High-resolution melting analysis of sequence variations in the Cytidine Deaminase Gene (CDA) in patients with cancer treated with gemcitabine

Therapeutic Drug Monitoring

Volumn 32, Issue 1, 2010, Pages 53-60

  Raynal, Caroline ^a,b   Ciccolini, Joseph ^c   Mercier, Cédric ^c   Boyer, Jean Christophe ^a   Polge, Anne ^a   Lallemant, Benjamin ^a   Mouzat, Kévin ^a,b   Lumbroso, Serge ^a,b   Brouillet, Jean Paul ^a,b   Evrard, Alexandre ^a,b  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

Cytidine deaminase; Gemcitabine; Genotyping; High resolution melting; Toxicity

Indexed keywords

CYTIDINE DEAMINASE; GEMCITABINE;

AGED; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ELIMINATION; ENZYME DEFICIENCY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; MALE; NEOPLASM; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BASE SEQUENCE; CYTIDINE DEAMINASE; DEOXYCYTIDINE; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MUTATION; NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; TRANSITION TEMPERATURE;

EID: 75649113362     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181c77c1b     Document Type: Article

References (39)

1. Liew M, Pryor R, Palais R, et al. Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem. 2004;50:1156-1164.
2. Wittwer CT, Reed GH, Gundry CN, et al. High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem. 2003;49:853-860.
3. Vandersteen JG, Bayrak-Toydemir P, Palais RA, et al. Identifying common genetic variants by high-resolution melting. Clin Chem. 2007;53: 11911198.
4. Schutz E, von Ahsen N. Influencing factors of dsDNA dye (high-resolution) melting curves and improved genotype call based on thermo-dynamic considerations. Anal Biochem. 2009;385:143-152.
5. Herrmann MG, Durtschi JD, Bromley LK, et al. Amplicon DNA melting analysis for mutation scanning and genotyping: cross-platform comparison of instruments and dyes. Clin Chem. 2006;52:494-503.
6. Kristensen LS, Dobrovic A. Direct genotyping of single nucleotide polymorphisms in methyl metabolism genes using probe-free high-resolution melting analysis. Cancer Epidemiol Biomarkers Prev. 2008;17: 1240-1247.
7. Norambuena PA, Copeland JA, Krenkova P, et al. Diagnostic method validation: High resolution melting (HRM) of small amplicons genotyp-ing for the most common variants in the MTHFR gene. Clin Biochem. 2009;42:1308-1316.
8. Montgomery J, Wittwer CT, Kent JO, et al. Scanning the cystic fibrosis transmembrane conductance regulator gene using high-resolution DNA melting analysis. Clin Chem. 2007;53:18911898.
9. Grievink H, Stowell KM. Identification of ryanodine receptor 1 single-nucleotide polymorphisms by high-resolution melting using the Light-Cycler 480 System. Anal Biochem. 2008;374:396-404.
10. Hung CC, Lin SY, Lee CN, et al. Identification of fibrillin-1 gene mutations in Marfan syndrome by high-resolution melting analysis. Anal Biochem. 2009;389:102-106.
11. Takano EA, Mitchell G, Fox SB, et al. Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis. BMC Cancer. 2008;8:59.
12. Nomoto K, Tsuta K, Takano T, et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol. 2006;126:608-615.
13. Krypuy M, Newnham GM, Thomas DM, et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer. 2006;6:295.
14. de Juan Jimenez I, Cardenosa EE, Suela SP, et al. Advantages of the high resolution melting in the detection of BRCA1 or BRCA2 mutation carriers. Clin Biochem. 2009;42:1572-1576.
15. Hill CE, Duncan A, Wirth D, et al. Detection and identification of cytochrome P-450 2C9 alleles *1, *2, and *3 by high-resolution melting curve analysis of PCR amplicons. Am J Clin Pathol. 2006;125:584-591.
16. Deeken JF, Figg WD, Bates SE, et al. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacoge-netics. Anticancer Drugs. 2007;18:111-126.
17. Bosch TM. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol Biol. 2008;448:63-76.
18. Morel A, Boisdron-Celle M, Fey L, et al. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem. 2007;40:11-17.
19. Yamauchi J, Kanai M, Matsumoto S, et al. Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer. Pancreas. 2008;36:327-328.
20. Dent S, Messersmith H, Trudeau M. Gemcitabine in the management of metastatic breast cancer: a systematic review. Breast Cancer Res Treat. 2008;108:319-331.
21. Natale R. A ten-year review of progress in the treatment of non-small-cell lung cancer with gemcitabine. Lung Cancer. 2005;50(Suppl 1):S2-S4.
22. Nagel S, Califano R, Thatcher N, et al. Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer. Exp Opin Pharmacother. 2007;8:3265-3275.
23. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212-2217.
24. Adjei AA. Clinical studies of pemetrexed and gemcitabine combinations. Ann Oncol. 2006;17(Suppl 5):V29-V32.
25. Mercier C, Raynal C, Dahan L, et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine de-aminase downregulation. Pharmacogenet Genomics. 2007;17:841-844.
26. Yonemori K, Ueno H, Okusaka T, et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res. 2005;11:2620-2624.
27. Danesi R, Altavilla G, Giovannetti E, et al. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics. 2009;10:69-80.
28. Mini E, Nobili S, Caciagli B, et al. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17(Suppl 5):V7-V12.
29. Kiani A, Kohne CH, Franz T, et al. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother Pharmacol. 2003;51:266-270.
30. Gilbert JA, Salavaggione OE, Ji Y, et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res. 2006;12:1794-1803.
31. Sugiyama E, Kaniwa N, Kim SR, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol. 2007;25:32-42.
32. Giovannetti E, Laan AC, Vasile E, et al. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids. 2008;27:720-725.
33. Mercier C, Evrard A, Ciccolini J. Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results. J Clin Oncol. 2007;25:4855; author reply 4855-4856.
34. Lyon E, Wittwer CT. LightCycler technology in molecular diagnostics. J Mol Diagn. 2009;11:93-101.
35. Okamura T, Kigasawa K, Takeuchi T, et al. Cytidine deaminase activity in abnormal pregnancy. Int J Gynaecol Obstet. 1993;41:53-60.
36. Okamura T, Kigasawa K. Re-evaluation of the colorimetric assay for cytidine deaminase activity. Prenat Diagn. 1994;14:213-218.
37. Hubbard TJ, Aken BL, Beal K, et al. Ensembl 2007. Nucleic Acids Res. 2007;35:D610-D617.
38. Funke S, Brenner H, Chang-Claude J. Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics. 2008;9:1079-1099.
39. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14:1797-1803.